|
US2019269645A1
|
|
Use of ferric citrate in the treatment of chronic kidney disease patients
|
|
KR20170123664A
|
|
Use of citrate in the treatment of iron-deficiency anemia
|
|
CA2928200A1
|
|
Ferric citrate for reducing cardiac failure in chronic kidney disease patients
|
|
AU2014218455A1
|
|
Ferric Citrate Dosage Forms
|
|
NZ742524A
|
|
Use of ferric citrate in the treatment of chronic kidney disease patients
|
|
MX2014015615A
|
|
Use of ferric citrate in the treatment of chronic kidney disease patients.
|
|
UA107803C2
|
|
DOSAGE FORM OF IRON CITRATE (iii)
|
|
CN109223724A
|
|
Ferric citrate dosage forms
|
|
WO2008060567A1
|
|
Glycosaminoglycan formulations in the treatment of vascular disease
|
|
AU2006244446A1
|
|
Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy
|
|
EP1804810A1
|
|
Methods using glycosaminoglycans for the treatment of kidney disease
|
|
US2007173479A1
|
|
Methods Using Sulodexide for the Treatment of Bladder Disease
|
|
IL159259D0
|
|
Methods using glycosaminoglycans for the treatment of nephropathy
|
|
US2003078400A1
|
|
Compounds for the modulation of kinase associated signal transduction
|
|
NZ530037A
|
|
Use of glycosaminoglycans for the treatment of HIV-associated nephropathy
|
|
US2003008844A1
|
|
Use of sulodexide for the treatment of inflammatory bowel disease
|
